诺和诺德“依柯胰岛素司美格鲁肽复方”在华获批上市

医药魔方
Mar 06

3月6日,国家药监局官网显示,诺和诺德的依柯胰岛素司美格鲁肽注射液(IcoSema)获批上市,用于治疗2型糖尿病。依柯胰岛素司美格鲁肽注射液是诺和诺德开发的一款复方药物,内含依柯胰岛素(icodec)和司美格鲁肽两种活性成分。依柯胰岛素是一款超长效胰岛素制剂,人体内半衰期长达196h,已于2024年6月获国家药监局批准上市。司美格鲁肽是一款长效GLP-1受体(GLP-1R)激动剂,人体内半衰期长达...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10